Merz nabs Allergan exec to head US neurosciences business

15 August 2017

Merz Neuroscience, a division of Merz North America, today announced that Kevin O’Brien will join the company as the vice president and US head of neurosciences, effective immediately.

Mr O’Brien will relocate to the Merz North America headquarters in Raleigh, North Carolina, which is part of German family-owned drugmaker Merz Pharma Group.

“We are honored to have Kevin join Merz with his proven track record of success leading sales and marketing teams globally and his extensive industry knowledge. He is highly collaborative and will be a strong and strategic addition to our leadership team,” commented Bob Rhatigan, president and chief executive of Merz North America.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK